Showing posts with label Mesenchymal Stem Cells. Show all posts
Showing posts with label Mesenchymal Stem Cells. Show all posts

Wednesday, 19 April 2017

Mesenchymal Stem Cells - Advances & Applications 2013 Industry Key Trends, Size, Growth, Shares And Forecast Research Report

Researchmoz added Most up-to-date research on "Mesenchymal Stem Cells - Advances & Applications 2013" to its huge collection of research reports.

Understand and profit from the mesenchymal stem cell (MSC) product market – the fastest growing area of stem cell research.

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

Trend analysis of grant activity, scientific publication rates, and patent applications trends reveal that global research activity involving mesenchymal stem cells (MSCs) increased 112% from 2009 to 2010, and 116% from 2010 to 2011. Of most interest is that this rate of growth accelerated throughout 2011, making mesenchymal stem cells the fastest growing area of stem cell research.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=174818

Because mesenchymal stem cell researchers represent a rapidly growing, well-funded research community, this report presents strategies for research supply companies to use to develop high-demand products for this community. A key element of this report is a survey of mesenchymal stem cell (MSC) researchers. This survey reveals critical findings that include:

- Preferred Tissue Source for MSCs
- Preferred Species Source for MSCs
- MSC Product Preferences
- Most Commonly Utilized MSC Antibodies
- Terms Used in Online Search (for targeting your ads with precision)

It is also important for bio-pharmaceutical and pharma companies interested in mesenchymal stem cell therapy applications to understand underlying market forces, and in particular, to consider progressive areas of MSC research as opportunistic areas for drug and therapy development. This report presents a range of topics of interest to these companies as well, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

Highlights of this report include:

- Charts, Timelines, Metrics and Financials
- Rates of MSC Grants, Publications, and Patents
- Market Characterization and 5-Year Projections
- Breakdown of MSC Research Activity by Application, Species, Tissue Source
- Geographical Assessment of Market Demand
- Competitive Environment Analysis, by MSC Product Supplier
- Recent Product Evolution and Unmet Market Needs
- Online Advertising Assessment and Opportunities for Targeted Traffic
- Revealing Survey of Your Prospective Clients MSC Scientists
- End-User Wants, Technical Preferences, Factors Influencing Buying Decisions

And Much More...

The market intelligence contained in this report was compiled using a broad range of sources, including:
- MSC grant funding (NIH database, DoD database)
- MSC patents (USPTO)
- MSC publications (PubMed, Highwire Press)
- MSC product launch announcements (Google News, Trade Journals)
- International surveys (electronically distributed end-user surveys)

And more

These sources were used to identify recent advances in MSC research applications, explore research priorities by market segment, highlight individual labs and end-users of MSC research products, explore the competitive environment for MSC research products, and provide 5-year growth and trend analysis. As such, this market intelligence report will advantageously position your company to offer competitive MSC products to this rapidly growing, well-funded research community.

You'll also access information on:

- Recent Product Evolution
- Projected Directions for Development
- Overview of Therapeutic Progress and Insight into Future Applications
- Detailed Evaluation of Profit Opportunities for Research Product Suppliers

In summary, literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has become huge in less than 10 years, now totaling nearly 13,000 publications, although some data does present as contradictory, suggesting a heterogenic nature for MSC populations depending on source tissue, species, and donor characteristics. MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, but have advantages in terms of availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.

Characterized by these properties, it not surprising that trend analysis reveals rapid increases in research activity involving mesenchymal stem cells. With scientific publication rate increases of 112% year-over-year from 2009 to 2010, and 116% from 2010 to 2011, this report will help you understand and profit from the mesenchymal stem cell (MSC) product market – the fastest growing area of stem cell research.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=174818

Tuesday, 18 April 2017

Latest Research Report on Mesenchymal Stem Cells - Advances & Applications | Researchmoz.us

Researchmoz added Most up-to-date research on "Mesenchymal Stem Cells - Advances & Applications" to its huge collection of research reports.

EXECUTIVE SUMMARY

This global strategic report is produced for:

- Management of stem cell companies
- Management of regenerative therapy companies
- Stem cell industry investors

It is designed to increase your efficiency and effectiveness in:

- Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
- Making intelligent investment decisions
- Launching high-demand products
- Selling effectively to your client base
- Increasing revenue from MSC products and services
- Taking market share from your competition

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=301052

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

Literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has expanded rapidly over the past 10 years, with more than 13,000 publications now exploring aspects of MSC biology, behavior, and applications. In particular, MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, while having advantages in terms of availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.

Clinical Progress with MSCs

As mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy.

The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to:

- Migrate to sites of inflammation caused by tissue injury when injected intravenously
- To get differentiated into different cell types
- To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
- To accomplish immunomodulatory functions

Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies.

Since 1968, bone marrow transplantation (BMT) has been the gold standard treatment for blood cancer patients and others with genetic blood disorders. Each year more than 60,000 bone marrow transplantations are performed worldwide, and 58% of these procedures use autologous bone marrow and 42% of the cases use allogeneic bone marrow. Currently, the use of bone marrow is being replaced by the utilization of MSCs for some conditions.

The majority of cell therapy products currently being marketed are meant to address musculoskeletal conditions, and most of these products use MSCs as a component.

Report Objectives

The purpose of this report is to describe the current status of mesenchymal stem cells (MSCs) research, the ongoing clinical trials involving MSCs, late stage MSCs clinical trials, and the possible uses of MSCs in cell therapy. As MSC cell therapy is an integrated component of other cell therapies and regenerative medicines (RM), the report also gives a brief overview of the RM industry and overall cell therapy (CT) industry.

Thus, the main objectives are to consider the following:

- Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
- Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
- Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
- The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.
- Key questions answered in this global strategic report are:
- How many companies are currently supporting the RM industry?
- What is the current regional breakdown of RM industry?
- How many RM products have been approved?
- What are the types of diseases are currently being pursued by RM companies?
- What are the major financial events, partnerships and acquisitions in RM sector?
- How do the large pharma companies perceive the value and long-term prospects of RM and CT?
- What are the major anticipated RM clinical events in 2015-16?
- What are the major therapeutic opportunities for the big pharma in RM and CT?
- How many CT product candidates have reached the Phase III stage and what are they?
- What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
- What are the major commercially available cell therapy products?
- What is the total number of cell therapy clinical trials at the global level?
- What are the major cell types used in cell therapy clinical trials?
- What are the major indications addressed by cell therapy clinical trials?
- What are the major cell therapy clinical trials that have reached Phase III?
- How many cell therapy clinical trials failed in the past year and what are they?
- What are the contributions of MSCs to the cell therapy industry?
- What are the biological properties of MSCs?
- What do MSCs get differentiated into?
- What bioactive molecules do the MSCs secrete?
- What are the immunomodulatory functions of MSCs?
- What are the factors impacting the acquisition of MSCs?
- What are the various sources of MSCs?
- What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
- What are the major clinical trials focusing on diabetes using BMMSCs?
- What are the major clinical trials involving BMMSCs for cardiovascular diseases?
- What are the major clinical trials focusing on liver diseases by BMMSCs?
- What are the brain-related diseases addressed by clinical trials using BMMSCs?
- How many clinical trials are conducted for intestinal diseases using MSCs?
- What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
- Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
- What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
- What is the current number of clinical trials using MSCs?
- How many major clinical trials using MSCs have reached the Phase III?
- What are the MSCs-based cell therapy products available in the market?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=301052

Wednesday, 23 November 2016

China Mesenchymal Stem Cells Industry Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "China Mesenchymal Stem Cells Industry 2016 Market Research Report" to its huge collection of research reports.

The China Mesenchymal Stem Cells Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Mesenchymal Stem Cells industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mesenchymal Stem Cells market analysis is provided for the China markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=725463

The report focuses on China major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Mesenchymal Stem Cells industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 148 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Contents

1 Industry Overview
1.1 Definition and Specifications of Mesenchymal Stem Cells
1.1.1 Definition of Mesenchymal Stem Cells
1.1.2 Specifications of Mesenchymal Stem Cells
1.2 Classification of Mesenchymal Stem Cells
1.3 Applications of Mesenchymal Stem Cells
1.4 Industry Chain Structure of Mesenchymal Stem Cells
1.5 Industry Overview of Mesenchymal Stem Cells
1.6 Industry Policy Analysis of Mesenchymal Stem Cells
1.7 Industry News Analysis of Mesenchymal Stem Cells

2 Manufacturing Cost Structure Analysis of Mesenchymal Stem Cells
2.1 Bill of Materials (BOM) of Mesenchymal Stem Cells
2.2 BOM Price Analysis of Mesenchymal Stem Cells
2.3 Labor Cost Analysis of Mesenchymal Stem Cells
2.4 Depreciation Cost Analysis of Mesenchymal Stem Cells
2.5 Manufacturing Cost Structure Analysis of Mesenchymal Stem Cells
2.6 Manufacturing Process Analysis of Mesenchymal Stem Cells
2.7 China Price, Cost and Gross of Mesenchymal Stem Cells 2011-2016

3 Technical Data and Manufacturing Plants Analysis
3.1 Capacity and Commercial Production Date of China Key Manufacturers in 2015
3.2 Manufacturing Plants Distribution of China Key Mesenchymal Stem Cells Manufacturers in 2015
3.3 R&D Status and Technology Source of China Mesenchymal Stem Cells Key Manufacturers in 2015
3.4 Raw Materials Sources Analysis of China Mesenchymal Stem Cells Key Manufacturers in 2015

4 Production Analysis of Mesenchymal Stem Cells by Regions, Type, and Applications
4.1 China Production of Mesenchymal Stem Cells by Regions 2011-2016
4.2 China Production of Mesenchymal Stem Cells by Type 2011-2016
4.3 China Sales of Mesenchymal Stem Cells by Applications 2011-2016
4.4 Price Analysis of China Mesenchymal Stem Cells Key Manufacturers in 2015
4.5 China Capacity, Production, Import, Export, Sales, Price, Cost and Revenue of Mesenchymal Stem Cells 2011-2016

5 Consumption Volume and Consumption Value Analysis of Mesenchymal Stem Cells by Regions
5.1 China Consumption Volume of Mesenchymal Stem Cells by Regions 2011-2016
5.2 China Consumption Value of Mesenchymal Stem Cells by Regions 2011-2016
5.3 China Consumption Price Analysis of Mesenchymal Stem Cells by Regions 2011-2016

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=725463

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...